| Previous close | 1,724.25 |
| Open | 1,724.25 |
| Bid | 1,727.00 x N/A |
| Ask | 1,755.50 x N/A |
| Day's range | 1,724.25 - 1,724.25 |
| 52-week range | 1,705.00 - 2,798.00 |
| Volume | |
| Avg. volume | 15 |
| Market cap | 110.589B |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | 20.79 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
COPENHAGEN, Denmark, June 28, 2024--Genmab A/S (Nasdaq: GMAB) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of conditional marketing authorization of epcoritamab (TEPKINLY®), a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more line
- GlobeNewswire
Completion of Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; June 27, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2024. On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program was expected to be completed no later than December 16, 2024. The following transactions were executed under the program from June 24, 2024, to June 26, 2024: Trading PlatformNo.
- Business Wire
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
COPENHAGEN, Denmark, June 26, 2024--Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. With this approval, EPKINLY is the first and only T-cell engaging bispecific antibody administered subcutaneously approved in the U.S. to treat this patient population. This indication is approved und
